Current Opinion in Cardiology最新文献

筛选
英文 中文
Elevated C-reactive protein and cardiovascular risk. c反应蛋白升高与心血管疾病风险。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-02-27 DOI: 10.1097/HCO.0000000000001215
Jia Ee Chia, Song Peng Ang
{"title":"Elevated C-reactive protein and cardiovascular risk.","authors":"Jia Ee Chia, Song Peng Ang","doi":"10.1097/HCO.0000000000001215","DOIUrl":"10.1097/HCO.0000000000001215","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review critically examines the evolving role of C-reactive protein (CRP) in cardiovascular disease (CVD), addressing its pathogenesis and relationship with various CVDs including coronary artery disease (CAD), heart failure, and atrial fibrillation.</p><p><strong>Recent findings: </strong>CRP is mechanistically implicated in endothelial dysfunction, oxidative stress, and plaque destabilization. Recent studies demonstrate that lipid-lowering agents (statins, bempedoic acid) and anti-inflammatory therapies (canakinumab, colchicine) reduce CRP levels and improve outcomes in CAD. In heart failure, elevated CRP predicts adverse events, though evidence on phenotypes varies, and novel therapies (glucagon-like peptide-1 agonists, sodium-glucose cotransporter-2 inhibitors) lower CRP independently of weight loss. For atrial fibrillation, CRP correlates with postoperative incidence and recurrence postablation, though data remain inconsistent. Guidelines offer differing opinion with the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines cautiously endorsing CRP for risk stratification in intermediate-risk individuals, while European guidelines advise against its routine use for primary prevention, reflecting unresolved questions about CRP's additive value.</p><p><strong>Summary: </strong>CRP remains a pivotal inflammation biomarker in CVD, yet its causal role and clinical applicability require clarification. While CRP-guided therapies show promise, discrepancies in guidelines highlight the need for robust trials to determine whether targeting CRP directly improves outcomes. Future research should focus on CRP's pathophysiological mechanisms and validate its utility in personalized CVD management.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"237-243"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From C-reactive protein to climate change: risk predictors for cardiovascular diseases beyond low-density lipoprotein cholesterol. 从c反应蛋白到气候变化:低密度脂蛋白胆固醇以外心血管疾病的风险预测因子。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1097/HCO.0000000000001232
Debabrata Mukherjee, Dimitri P Mikhailidis
{"title":"From C-reactive protein to climate change: risk predictors for cardiovascular diseases beyond low-density lipoprotein cholesterol.","authors":"Debabrata Mukherjee, Dimitri P Mikhailidis","doi":"10.1097/HCO.0000000000001232","DOIUrl":"10.1097/HCO.0000000000001232","url":null,"abstract":"","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"40 4","pages":"213-214"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Near infrared spectroscopy in the pediatric cardiac intensive care unit: accurately interpreting the data. 近红外光谱在儿童心脏重症监护病房:准确地解释数据。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-02-12 DOI: 10.1097/HCO.0000000000001204
Ilias Iliopoulos, Saul Flores, Rohit Loomba
{"title":"Near infrared spectroscopy in the pediatric cardiac intensive care unit: accurately interpreting the data.","authors":"Ilias Iliopoulos, Saul Flores, Rohit Loomba","doi":"10.1097/HCO.0000000000001204","DOIUrl":"10.1097/HCO.0000000000001204","url":null,"abstract":"<p><strong>Purpose of review: </strong>Near infrared spectroscopy (NIRS) has been increasingly adopted as standard monitoring in postoperative care of pediatric cardiac patients. Several reports have established its association with both markers of perfusion and adverse outcomes. The correlation with markers of perfusion is not strong and exhibits wide limit of agreement, making the determination of critical thresholds and its integration in treatment algorithms challenging.</p><p><strong>Recent findings: </strong>A growing body of literature support the use of NIRS for hemodynamic monitoring in pediatric cardiac patients. Recent reports corroborate prior findings of weak to moderate correlation of NIRS with markers of global and regional perfusion and confirm its association with adverse outcomes. The challenge of lack of treatment thresholds remains, limiting clinical utility. Evidence of improvement of outcomes with the use of NIRS remains limited.</p><p><strong>Summary: </strong>NIRS is a useful monitor of regional and global perfusion and can inform management decisions but cannot be used as the sole decision-making tool. Large, randomized studies are needed to define its use as decision making tool and facilitate its integration in treatment algorithms.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"282-289"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurodevelopmental outcomes in congenital heart disease: modifiable and nonmodifiable substrates. 先天性心脏病的神经发育结局:可改变和不可改变的基础。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-05-13 DOI: 10.1097/HCO.0000000000001218
Kelly Wolfe, Shabnam Peyvandi
{"title":"Neurodevelopmental outcomes in congenital heart disease: modifiable and nonmodifiable substrates.","authors":"Kelly Wolfe, Shabnam Peyvandi","doi":"10.1097/HCO.0000000000001218","DOIUrl":"10.1097/HCO.0000000000001218","url":null,"abstract":"<p><strong>Purpose of review: </strong>Neurodevelopmental impairments are the most common comorbidity among children, adolescents, and adults with congenital heart disease (CHD). Despite significant advances in operative and perioperative care resulting in increased survival, neurodevelopmental impairments remain prevalent in this population. Neurodevelopmental impairments, though subtle, can have a major impact on quality of life, attainment of independence and societal contribution. In this review, we summarize current knowledge on neurodevelopmental outcomes in the CHD population, including neuroimaging findings, known risk factors and opportunities to optimize outcomes.</p><p><strong>Recent findings: </strong>Several risk factors have been identified contributing to neurodevelopmental impairments across the lifespan. These include risk factors originating in the prenatal period and new risk factors that are acquired in adulthood. The risk factors encompass several categories, including genetic abnormalities, aberrant cardiovascular physiology, environmental factors, social determinants of health and mental health. Many risk factors can be considered modifiable, though large multicenter studies identifying the most salient risk factors for neurodevelopmental impairment are lacking.</p><p><strong>Summary: </strong>In this review, we identify potentially modifiable risk factors for neurodevelopmental impairment in the CHD population that can be studies in future neuroprotective clinical trials.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"259-264"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Climate change and cardiovascular risk. 气候变化和心血管风险。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-02-12 DOI: 10.1097/HCO.0000000000001207
Song Peng Ang, Jia Ee Chia
{"title":"Climate change and cardiovascular risk.","authors":"Song Peng Ang, Jia Ee Chia","doi":"10.1097/HCO.0000000000001207","DOIUrl":"10.1097/HCO.0000000000001207","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review explores the complex relationship between climate change and cardiovascular health. It examines the mechanisms through which climate change impacts cardiovascular risk, highlights recent findings on regional trends, and discusses mitigation strategies.</p><p><strong>Recent findings: </strong>Climate change significantly contributes to cardiovascular morbidity and mortality through mechanisms such as temperature extremes, air pollution, and food insecurity. Heatwaves increase risks of dehydration, electrolyte imbalance, and acute cardiovascular events, while cold spells exacerbate myocardial stress and pollution-related cardiovascular risks. Air pollution, including fine particulate matter (PM2.5), induces systemic inflammation, endothelial dysfunction, and atherosclerosis. Emerging data highlight regional variations, with urbanization exacerbating risks in Asia-Pacific and Middle Eastern populations, while extreme heat and cold challenge resilience in Europe and Latin America. Studies also link socioeconomic stress from climate-induced displacement and resource shortages to chronic cardiovascular conditions. Notably, urban greening and air quality regulations demonstrate potential for reducing cardiovascular risks.</p><p><strong>Summary: </strong>Climate change amplifies cardiovascular risks through diverse mechanisms, disproportionately affecting vulnerable populations. Targeted strategies, including public health campaigns, sustainable urban planning, and technological innovations, can mitigate these risks. Advances in generative artificial intelligence and big data analytics offer opportunities to tailor interventions and enhance predictive modeling. A multidisciplinary approach integrating public health, environmental science, and clinical expertise is critical to addressing these challenges. Urgent action is required to mitigate the long-term cardiovascular impacts of climate change and foster resilient health systems globally.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"244-250"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension after solid-organ transplantation: special considerations for management. 实体器官移植后高血压:处理的特殊考虑。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/HCO.0000000000001230
Jason Feliberti, Amit Alam, Christopher Maulion
{"title":"Hypertension after solid-organ transplantation: special considerations for management.","authors":"Jason Feliberti, Amit Alam, Christopher Maulion","doi":"10.1097/HCO.0000000000001230","DOIUrl":"10.1097/HCO.0000000000001230","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypertension is one of the most common comorbidities affecting patients after solid organ transplantation. Here we review the mechanisms leading to hypertension, along with common practices in terms of medical management. Glucagon-like peptide-1 receptor (GLP-1R) agonists, baroreflex therapy, and renal denervation are common interventions utilized prior to heart transplant. Special considerations for their management throughout the perioperative and postoperative period are covered here.</p><p><strong>Recent findings: </strong>Most common medical management includes utilization of calcium channel blockers, followed by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. GLP-1R agonists have shown significant benefit in recent cardiovascular outcome trials. Preoperative management centers around risks associated with slowed gastric emptying, while reinitiation after heart transplant must take into consideration initiation and tolerance of immunosuppressive therapies. Baroreflex activation therapy has been approved for therapy of heart failure, with many patients proceeding to heart transplant. The device is frequently deactivated after transplantation, with little published experience regarding reinitiation of therapy after heart transplant. There is renewed interest in renal denervation as a treatment for refractory hypertension. The incidence of hypertension after heart transplant in those patients that have undergone previous renal denervation remains unknown, however there is limited experience with its use after renal transplant.</p><p><strong>Summary: </strong>Further studies are required to elucidate optimal medical management of hypertension following heart transplantation. GLP-1R agonists, baroreflex activation therapy, and renal denervation are emerging therapies prior to transplant that require further investigation.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"193-198"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin-Associated muscle symptoms and vitamin D supplementation. 他汀类药物相关肌肉症状和维生素D补充
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-04-24 DOI: 10.1097/HCO.0000000000001222
Kahtan Fadah, Adriana Mares, Richard A Lange
{"title":"Statin-Associated muscle symptoms and vitamin D supplementation.","authors":"Kahtan Fadah, Adriana Mares, Richard A Lange","doi":"10.1097/HCO.0000000000001222","DOIUrl":"10.1097/HCO.0000000000001222","url":null,"abstract":"<p><strong>Purpose of review: </strong>Statin medications play a pivotal role in the primary and secondary prevention and management of cardiovascular disease due to their potent lipid-lowering and anti-inflammatory effects. Nevertheless, the clinical application of statins is often hampered by statin-associated muscle symptoms (SAMS), which deter patient adherence and treatment efficacy considerably. SAMS currently affects 10-20% of statin users, thus understanding potential mitigation strategies is crucial. This review focuses on the role of vitamin D in mitigating SAMS, given the growing interest in vitamin D deficiency as a potentially modifiable risk factor.</p><p><strong>Recent findings: </strong>Despite observational suggestions linking vitamin D deficiency to heightened SAMS risk, recent studies have yielded conflicting results on the role of vitamin D supplementation in preventing SAMS. Some studies report an improvement in statin tolerance following vitamin D repletion. However, recent large-scale clinical trials, particularly the Vitamin D and Omega-3 trial (VITAL) report no significant benefit of vitamin D supplementation in preventing SAMS or reducing statin discontinuation rates, regardless of baseline vitamin D levels.</p><p><strong>Summary: </strong>Observational data provides evidence for the use of vitamin D supplementation in SAMS management, however conflicting evidence in recent clinical trials do not support its routine use for preventing or treating SAMS. To explore alternative strategies in improving statin tolerance and adherence, this discourse aims to elucidate the current understanding the complex mechanisms underlying SAMS, the influence of serum vitamin D levels, and the implications for clinical management.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"215-220"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing acute supraventricular tachycardia and the role of intravenous sotalol. 急性室上性心动过速的治疗及静脉索他洛尔的作用。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-04-09 DOI: 10.1097/HCO.0000000000001223
Mitchell I Cohen, Robert Przybylski
{"title":"Managing acute supraventricular tachycardia and the role of intravenous sotalol.","authors":"Mitchell I Cohen, Robert Przybylski","doi":"10.1097/HCO.0000000000001223","DOIUrl":"10.1097/HCO.0000000000001223","url":null,"abstract":"<p><strong>Purpose of review: </strong>The initial approach to stable supraventricular tachycardia (SVT) in children is either adenosine or vagal maneuvers. While automatic tachycardias do not respond to such an approach, even reentrant arrythmias will fail to terminate with adenosine or vagal maneuvers. Little consensus exists on the ideal second line antiarrhythmic medication for stable SVT. This article reviews the current approach to stable SVT and early pediatric studies using intravenous (i.v.) sotalol.</p><p><strong>Recent findings: </strong>The development of i.v. sotalol has spawned enthusiasm for a novel antiarrhythmic for refractory reentrant SVT and other automatic atrial tachycardias. Retrospective pediatric multicenter studies have shown an excellent conversion (50-90%) of refractory SVT with a single dose of i.v. sotalol; generally, over 30 min. Cautioned should be exercised using i.v. sotalol in patients with ventricular dysfunction and dose adjustments need to be made based on creatinine clearance. In addition, i.v. sotalol has shown promising early results in slowing the ventricular rate in postoperative junctional ectopic tachycardia faster than i.v. amiodarone.</p><p><strong>Summary: </strong>Intravenous sotalol has shown promising results in refractory pediatric SVT. Protocol driven dosing with the help of hospital pharmacists should be established before i.v. sotalol is prescribed. Future prospective studies especially in postoperative patients, neonates and patients with congenital heart disease are needed.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"290-297"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary vein stenosis: future optimism. 肺静脉狭窄:未来乐观。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-04-09 DOI: 10.1097/HCO.0000000000001217
Patcharapong Suntharos, Marin Satawiriya, Lourdes R Prieto
{"title":"Pulmonary vein stenosis: future optimism.","authors":"Patcharapong Suntharos, Marin Satawiriya, Lourdes R Prieto","doi":"10.1097/HCO.0000000000001217","DOIUrl":"10.1097/HCO.0000000000001217","url":null,"abstract":"<p><strong>Purpose of review: </strong>Pulmonary vein stenosis (PVS) is a rare disease with high morbidity and mortality. Prevention of restenosis remains challenging. This review will highlight recent advances in therapy that are beginning to show a survival benefit.</p><p><strong>Recent findings: </strong>Intervention for multivessel pediatric PVS may be surgical or transcatheter, both with high restenosis rates. At a threshold upstream diameter of 7 mm, the risk of restenosis decreases. Close vigilance and frequent reinterventions, typically transcatheter, are now accepted practice to maintain vein patency and achieve upstream growth. Suppressive agents targeting the exuberant myofibroblastic proliferation characteristic of PVS, specifically sirolimus, delivered locally on the surface of balloons and stents, and as adjunct systemic therapy, have been shown to increase survival and decrease reinterventions. Newer surgical techniques focused on shortening and straightening the vein to optimize flow dynamics, coupled with hybrid intraoperative stent placement in selected cases, also show a survival benefit.Adult-onset PVS, most commonly a complication of pulmonary vein isolation, now occurs rarely, and generally responds to transcatheter intervention. Further advances in ablation techniques aim to eliminate this complication.</p><p><strong>Summary: </strong>An aggressive approach of frequent reinterventions is a necessary strategy rather than treatment failure. More granular understanding of the mechanisms underlying PVS leading to novel muti-pronged anatomic and suppressive therapy are yielding improved survival.Multispecialty PVS teams at the institutional level and multiinstitutional collaboration, now possible via the PVS registry, are crucial to optimal care and future progress.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"298-304"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anesthetic management in patients with long QT and Brugada syndromes. 长QT期综合征和Brugada综合征患者的麻醉处理。
IF 2 4区 医学
Current Opinion in Cardiology Pub Date : 2025-07-01 Epub Date: 2025-04-09 DOI: 10.1097/HCO.0000000000001220
Jordan A Cohen, Joseph Dayan
{"title":"Anesthetic management in patients with long QT and Brugada syndromes.","authors":"Jordan A Cohen, Joseph Dayan","doi":"10.1097/HCO.0000000000001220","DOIUrl":"10.1097/HCO.0000000000001220","url":null,"abstract":"<p><strong>Purpose of review: </strong>Both long QT and Brugada syndrome are inherited arrhythmic conditions that can predispose patients to life-threatening ventricular arrhythmias. Managing the anesthesia for patients with either long QT or Brugada syndrome necessitates an understanding of potential drug-drug interactions with the underlying channelopathy. This review illustrates contemporary insight into managing such patients for the anesthesiologist.</p><p><strong>Recent findings: </strong>Long QT, due to disorder of potassium or sodium ion channels, is associated with prolonged repolarization of the action potential phase. Medications that prolong the action potential should be avoided. In patients with long QT syndrome, each drug administered should be carefully reviewed to be certain it does not prolong the QT interval. Brugada syndrome is a result of a pathogenic sodium channel that results in potential ventricular arrhythmias. Medications that exacerbate the electrocardiographic changes of Brugada should be avoided.</p><p><strong>Summary: </strong>Anesthesiologists need to be aware of proper management in children with known or suspected long QT or Brugada pathologies as well as the potential poly-pharmaceutical impact that exists on cardiac ion channels.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"275-281"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信